Preclinical Research Progress of Endoplasmic Reticulum Stress Inhibitors in Respiratory Diseases
10.3870/j.issn.1004-0781.2025.09.015
- VernacularTitle:内质网应激抑制剂在呼吸系统疾病中的临床前研究进展
- Author:
Huiyun LIAO
1
;
Yao FANG
;
Lei QU
;
Haichao LIU
;
Congzheng MAO
;
Qiong TANG
;
Zhenhong HU
Author Information
1. 武汉科技大学医学部医学院,武汉 430065;中部战区总医院呼吸与危重症医学科,武汉 430070
- Publication Type:Journal Article
- Keywords:
Endoplasmic reticulum stress inhibitors;
Endoplasmic reticulum stress;
Unfolded protein response;
Respiratory diseases
- From:
Herald of Medicine
2025;44(9):1472-1476
- CountryChina
- Language:Chinese
-
Abstract:
Endoplasmic reticulum stress(ERS)is associated with the pathophysiology of various lung diseases.Multiple experiments have confirmed that inhibiting ERS can alleviate inflammatory responses,improve lung function,and possess certain anti-infective effects.ERS inhibitors can positively impact the treatment of respiratory system diseases by targeting the unfolded protein response(UPR)in the ERS pathway and regulating the balance of calcium ions within the endoplasmic reticulum.Most current research on ERS inhibitors is still in the preclinical stage.This article thoroughly reviews the relevant reviews and various experimental research results on ERS in respiratory diseases,systematically examining the potential roles of the main branches of UPR,including inositol requiring enzyme 1 alpha(IRE 1α),protein kinase-like endoplasmic reticulum kinase(PERK),and activated transcription factor 6(ATF6),as well as other ERS inhibitors in respiratory diseases.The aim is to promote clinical trial exploration of ERS inhibitors,with the hope of providing effective drug selection strategies for the treatment and symptom relief of respiratory diseases.
